Table 1 Patient characteristics and assessment of statistically significant differences among both study cohorts with regards to clinical and histopathological risk factors as well post-primary treatment
Category | M-ETE | TCT | p-value | |
|---|---|---|---|---|
Sex | Male, n (%) | 20 (25.0 %) | 23 (28.7 %) | 0.72 |
Female, n (%) | 60 (75.0 %) | 57 (71.3 %) | ||
Age | Mean (years) | 48.6 (10–78) | 45.1 (16–75) | |
> 55 years, n (%) | 24 (30.0 %) | 20 (25.0 %) | 0.60 | |
Histo-pathology | PTC, n (%) | 69 (86.3 %) | 69 (86.3 %) | |
FTC, n (%) | 11 (13.8 %) | 11 (13.8) | ||
Tumor size (mm) | 22.1 | 21.9 | 0.93 | |
Multifocal tumor, n (%) | 16 (20.0 %) | 17 (21.3 %) | 1.00 | |
R1 resection, n (%) | 15 (18.8 %) | 8 (10.0 %) | 0.18 | |
Post-primary treatment | EBRT, n (%) | 13 (16.3 %) | 1 (1.3 %) | 0.001 |
Median cumulative131Iodine activity (GBq) | 10.0 (range: 0–31) | 8.0 (range: 0–27) | < 0.001 |